Qing‐Dai for pediatric ulcerative colitis multicenter survey & systematic review

Background

Pediatric ulcerative colitis (UC) is more challenging to treat than adult UC. Qing-Dai therapy is effective in adults, but reports of its efficacy in children are unavailable. We conducted a questionnaire survey on Qing-Dai usage among pediatric patients with UC in Japan to determine its efficacy and safety.

Methods

Questionnaires were sent to 31 high-volume centers treating pediatric patients with inflammatory bowel disease. The number of patients using Qing-Dai, short-term and long-term effects, and adverse events were assessed. A systematic review of studies on the efficacy and safety of Qing-Dai usage for UC was also performed.

Results

Overall, 29/31 facilities (93.6%) responded, Qing-Dai was used in 107 patients with UC, and 84/107 patients (78.6%) initiated treatment. Within 6 months, 81/101 (80.2%) patients had clinical remission, while 59/92 (64.1%) patients had no relapse and 29/92 (31.5%) experienced only one to two relapses yearly. Eighty-seven percent of the patients underwent regular follow-ups for adverse events, among whom one was diagnosed with pulmonary arterial hypertension (PAH), five with enteritis, and one with headache. In the systematic review, the clinical remission rate was 50–80%, and PAH was observed in 14 of 1158 patients (1.2%).

Conclusions

Qing-Dai is highly effective in treating pediatric UC. However, Qing-Dai should be administered with caution as it may cause adverse events such as PAH.

留言 (0)

沒有登入
gif